Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Rudin

Showing results (361-370 of 524) with videos related to

Pageof 53
Sort By:
Nature Reviews. Cancer|June 9, 2019
Author Correction: Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model dataCharles M Rudin, John T Poirier, Lauren Averett Byers, et al.
The New England Journal of Medicine|September 4, 2009
Inhibition of the hedgehog pathway in advanced basal-cell carcinomaDaniel D Von Hoff, Patricia M LoRusso, Charles M Rudin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 14, 2023
Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 AmplificationArielle Elkrief, Igor Odintsov, Vladimir Markov, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 11, 2022
APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomasP Selenica, A Marra, N J Choudhury, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2020
A Self-Assembling and Disassembling (SADA) Bispecific Antibody (BsAb) Platform for Curative Two-step Pretargeted RadioimmunotherapyBrian H Santich, Sarah M Cheal, Mahiuddin Ahmed, et al.
Cell Reports|December 2, 2020
Concurrent Mutations in STK11 and KEAP1 Promote Ferroptosis Protection and SCD1 Dependence in Lung CancerCorrin A Wohlhieter, Allison L Richards, Fathema Uddin, et al.
Nature|September 17, 2025
Basal cell of origin resolves neuroendocrine-tuft lineage plasticity in cancerAbbie S Ireland, Daniel A Xie, Sarah B Hawgood, et al.
Cell Reports|May 18, 2022
WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLCHirokazu Taniguchi, Rebecca Caeser, Shweta S Chavan, et al.
Science (New York, N.Y.)|September 4, 2009
Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastomaRobert L Yauch, Gerrit J P Dijkgraaf, Bruno Alicke, et al.
Clinical Lung Cancer|October 1, 2016
Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor MutationsNatasha B Leighl, Naiyer A Rizvi, Lopes Gilberto de Lima, et al.
Pageof 53

Showing results (361-370 of 524) with videos related to

Sort By:
Pageof 53
Nature Reviews. Cancer|June 9, 2019
Author Correction: Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model dataCharles M Rudin, John T Poirier, Lauren Averett Byers, et al.
The New England Journal of Medicine|September 4, 2009
Inhibition of the hedgehog pathway in advanced basal-cell carcinomaDaniel D Von Hoff, Patricia M LoRusso, Charles M Rudin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 14, 2023
Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 AmplificationArielle Elkrief, Igor Odintsov, Vladimir Markov, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 11, 2022
APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomasP Selenica, A Marra, N J Choudhury, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2020
A Self-Assembling and Disassembling (SADA) Bispecific Antibody (BsAb) Platform for Curative Two-step Pretargeted RadioimmunotherapyBrian H Santich, Sarah M Cheal, Mahiuddin Ahmed, et al.
Cell Reports|December 2, 2020
Concurrent Mutations in STK11 and KEAP1 Promote Ferroptosis Protection and SCD1 Dependence in Lung CancerCorrin A Wohlhieter, Allison L Richards, Fathema Uddin, et al.
Nature|September 17, 2025
Basal cell of origin resolves neuroendocrine-tuft lineage plasticity in cancerAbbie S Ireland, Daniel A Xie, Sarah B Hawgood, et al.
Cell Reports|May 18, 2022
WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLCHirokazu Taniguchi, Rebecca Caeser, Shweta S Chavan, et al.
Science (New York, N.Y.)|September 4, 2009
Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastomaRobert L Yauch, Gerrit J P Dijkgraaf, Bruno Alicke, et al.
Clinical Lung Cancer|October 1, 2016
Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor MutationsNatasha B Leighl, Naiyer A Rizvi, Lopes Gilberto de Lima, et al.
Pageof 53